| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.11 | 0.5 |
| mRNA | Sunitinib | FIMM | pan-cancer | AAC | 0.12 | 0.5 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.037 | 0.5 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.039 | 0.5 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |